and its 7-year open-label extension (OLE) (ClinicalTrials.gov Identifier: NCT00523341) to predict the likelihood of achieving T-score targets (> -2.5 or ≥ -2.0) at the total hip and lumbar spine over ...
Longer durations of denosumab treatment improved the probability of achieving target T-scores at the total hip and lumbar spine in postmenopausal ... and its 7-year open-label extension (OLE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback